Regeneron Pharmaceuticals, a leading biotechnology company specializing in the development of medicines, has acquired 23andMe’s gene-testing business. The deal focuses on leveraging 23andMe’s extensive genetic database to accelerate Regeneron’s drug discovery and development programs.

The acquisition encompasses 23andMe’s research and development assets related to drug discovery. This means Regeneron will gain access to 23andMe’s vast repository of anonymized genetic data and associated research insights.

23andMe’s core consumer-facing genetic testing and ancestry services, where individuals purchase tests to learn about their ancestry and health predispositions, are *not* included in this transaction. 23andMe will continue to operate these consumer-facing segments independently.

The financial terms of the deal were not publicly disclosed, meaning the purchase price remains undisclosed. Further details regarding the deal’s structure are also yet to be fully unveiled.

Regeneron plans to use the acquired data to identify new drug targets, to find genetic connections that could point to potential treatments for various diseases. The aim is to enhance the speed and effectiveness of its drug development pipeline.

The partnership marks a significant shift for 23andMe, which is known for its direct-to-consumer genetic testing. It indicates a strategic move towards focusing on its consumer services while maximizing the value of its scientific assets.

This strategic focus will allow 23andMe to concentrate on the continued improvement of its consumer facing service, which is where it generates the most revenue. It also allows them to profit from their existing genetic data and research.

The move also potentially benefits 23andMe’s existing research data by seeing it put to good use. There are high hopes that the data will contribute to the discovery of drugs.

For Regeneron, the acquisition offers a valuable resource to bolster its already significant drug development efforts. Access to 23andMe’s data can help them better understand diseases at a genetic level.

This deal highlights the growing importance of genetic information in the pharmaceutical industry and the increasing collaborations between consumer genetics companies and established pharmaceutical firms, shaping the landscape of medical research.